-
05-06-2023, 10:23 AM
#441
Member
One step to go....wonder how long that will take?
-
05-06-2023, 10:43 AM
#442
Originally Posted by herbert240
One step to go....wonder how long that will take?
Only one more step? Which one are you talking about?
1) Plan plant and operation
2) Fund it (capital raise)
3) set it up
4) operate it and monitor the results
5) based on the results in (4) - modify / optimise operation
and go back to (4) or go to (6)
6) if shareholder good will left, go back to (1) otherwise go to (7)
7) Exit
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
-
05-06-2023, 11:42 AM
#443
Member
No I was referring to link in Southern Lad's post which said the final regulatory step is an acquaculture decision to be made by the Ministry for Primary Industries (MP!)
-
06-06-2023, 08:57 AM
#444
https://www.nzx.com/announcements/412533
Mediated Settlement to NZKS Blue Endeavour Consent
-
12-09-2023, 06:13 PM
#445
Snippet from Sanford's recent update, sounds pretty upbeat about Salmon pricing and demand.
Bodes well with their $21-25m Ebitda forecast.
24/8/23 "Pricing remains strong for the Salmon division, up 20.3% on pcp. Sales volumes remain consistent with the same quarter in FY22 and with pre-covid sales levels" CEO Craig Ellison says: “Pricing remains encouraging for all divisions, and it is pleasing that demand, particularly in export markets, is strong.”
“Salmon continues to be the standout for the group with strong demand for King Salmon and the Big Glory Bay brand. Risk mitigation initiatives introduced earlier in the year have also helped keep the salmon healthy and reduce the impact of mortalities.”
-
14-09-2023, 04:27 PM
#446
Member
Originally Posted by silverblizzard888
Snippet from Sanford's recent update, sounds pretty upbeat about Salmon pricing and demand.
Bodes well with their $21-25m Ebitda forecast.
24/8/23 "Pricing remains strong for the Salmon division, up 20.3% on pcp. Sales volumes remain consistent with the same quarter in FY22 and with pre-covid sales levels" CEO Craig Ellison says: “Pricing remains encouraging for all divisions, and it is pleasing that demand, particularly in export markets, is strong.”
“Salmon continues to be the standout for the group with strong demand for King Salmon and the Big Glory Bay brand. Risk mitigation initiatives introduced earlier in the year have also helped keep the salmon healthy and reduce the impact of mortalities.”
If NZK do go-ahead there is a big future for them in this market ,and as someone already said salmon from the ocean/sea is far superior to the mount Cook variety .
And all the healthy eaters Diet conscious amongst us cannot get enough of it .
share price someday should bounce back !!!
-
14-09-2023, 05:55 PM
#447
Originally Posted by ralph
If NZK do go-ahead there is a big future for them in this market ,and as someone already said salmon from the ocean/sea is far superior to the mount Cook variety .
And all the healthy eaters Diet conscious amongst us cannot get enough of it .
share price someday should bounce back !!!
That's the thing with companies in distress - they either bounce back or they go broke.
The odds are on the second option, but hey - there is always hope.
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
-
15-09-2023, 10:46 AM
#448
Member
Totally but what are the odds !!
-
15-09-2023, 11:24 AM
#449
Originally Posted by ralph
Totally but what are the odds !!
That's the 64 million Dollar question ...
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
-
21-09-2023, 09:10 AM
#450
Decent improvement.....
https://www.nzx.com/announcements/418597
New Zealand King Salmon Investments Ltd (NZX & ASX: NZK) reports its financial performance for the six-month period ended 31 July 2023 (1HY24).
Key points include:
• 1HY24 net profit for the year of $10.6 million, compared to a net loss of $24.5 million in 1HY23.
• 1HY24 pro-forma EBITDA of $10.7 million, compared to an EBITDA loss of $12.7 million in 1HY23.
• Sales volumes increased from 2,885MT in 1HY23 to 3,024MT in 1HY24 (an increase of 5%).
• Revenues increased from $80.0 million in 1HY23 to $91.6 million in 1HY24 (an increase of 14%).
• The mortality cost decreased from $22.3 million in 1HY23 to $7.8m in 1HY24.
• Earnings guidance range of pro-forma EBITDA has been revised up to $23.5m - $27.5m (Original guidance range of $21m - $25m provided to market in March 2023).
*1HY23 numbers restated as NZKS is no longer reversing the impacts of NZ IFRS 16 leases as previously communicated.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks